Camptothecin (CPT) was originally isolated from the bark of the Chinese tree, Camptotheca acuminate (Nyssaceae family), and is a DNA topoisomerase I (Top1) inhibitor that reversibly binds to Top1 cleavage complexes (Top1ccs). Several CPT derivatives are now commonly used in the treatment of certain human cancers, especially hepatocellular carcinoma.
Camptothecin (CPT) was originally isolated from the bark of the Chinese tree, Camptotheca acuminate (Nyssaceae family), and is a DNA topoisomerase I (Top1) inhibitor that reversibly binds to Top1 cleavage complexes (Top1ccs). Several CPT derivatives are now commonly used in the treatment of certain human cancers, especially hepatocellular carcinoma. 1, 2) The conversion of Top1ccs into irreversible Top1 covalent complexes results in DNA damage, induction of DNA repair mechanisms, and changes in expression for cellcycle proteins related to growth arrest and apoptosis; defects in key factors of these pathways are essential to the oncogenic process and related to the effects of Top 1 inhibitors. For example, CPT can activate poly(ADP-ribose) polymerase (PARP), which is involved in DNA-repair mechanisms and plays a crucial role in maintaining gene stability.
3) PARP-deficient and knockout cells have been shown hypersensitive to CPT and more susceptible to oncogenic transformation. 4) Furthermore, administration of a PARP inhibitor increased the anti-tumor activity of CPT derivatives in a mouse model. 5) Inhibitors of CHK1, 6,7) CHK2, 8) and nuclear factor (NF)-kB, 9) which are involved in CPT-induced cellular pathways, have also shown enhanced cytotoxicity when combined with CPT treatment.
Regulation of CHK1, CHK2, and NF-kB has extended the application of CPT to other disease states and produced promising results in several cancer clinical trials.
10) Nevertheless, further studies are necessary to discover additional factors involved in CPT-induced cellular responses. We analyzed several common gene expression patterns in four human tumor cell lines exposed to CPT using cDNA microarrays and found that multiple intracellular pathways were activated.
11) The goal of the present study was to use proteomics to identify proteins that change expression following treatment with CPT in the hepatocellular carcinoma cell line, SMMC-7721. We hypothesize that proteomic profiling may be useful to classify protein expression patterns of tumors with activated signaling pathways that would be sensitive to CPT. This type of study has the potential to develop molecular readouts of tumor signaling pathways so as to optimize therapies for rapid and effective treatment of specific types of cancer.
MATERIALS AND METHODS

Cell Culture and Cell Viability Assays
The human hepatocellular carcinoma cell line, SMMC-7721, was obtained from the Department of Biochemistry of the Second Military Medical University, Shanghai, China. Cell viability after treatment of CPT was evaluated using 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) assays. Cells were treated with dilutions of CPT of 1.36-330 mg/ml, cultured for 72 h, incubated with 250 mg/ml MTT for 4 h, and analyzed by microplate reader. For CPT and 5-aza-2Ј-deoxycytidine (DAC) co-treatment, cells were treated with 0.1 mM freshly prepared DAC. Treatment was replenished every 24 h and after 72 h, cells were washed with phosphae buffered saline (PBS) then incubated in drug-free media for 96 h. Cells were plated into 96-well plates, and 24 h later, were treated with CPT of 55 mg/ml for 48 h. Cell viability was determined using an MTT assay.
2-D Gel Electrophoresis SMMC-7721 cells were treated with 55 mg/ml CPT for 6 h. Cells were washed in PBS and resuspended in 150 ml rehydration/sample buffer (BioRad). Samples (150 mg) were applied on a dry isoelectric pH gradient (IPG) strip (170 mm, linear pH gradient 3.0-10.0, Bio-Rad). After rehydration at room temperature overnight, isoelectric focusing was performed in a Protean IEF System (Bio-Rad) according to the manufacturer's instructions. After equilibration the strips were separated on 12% sodium dodecyl sulfate (SDS) polyacrylamide gels run at 10 mA for 30 min and then at 25 mA until the bromphenol blue dye reached the end of the gel.
Identification via Mass Spectrometry Spots were excised, destained, and digested. Following a series of disposals, peptides were spotted onto a matrix assisted laser desorption/ionizaion (MALDI) target plate and spectra obtained by a mass spectrometer MALDI-time of flight (TOF)-MS/MS (ABI 4700). 12) Sequences were searched against the NCBI Human protein sequence database using MASCOT (Matrix Science, London, U.K.).
Quantitative Real-Time Reverse Transcription-Polymerase Chain Reaction (RT-PCR) Total RNA was isolated from exponentially growing cultures using Trizol reagent (Invitrogen). First-strand cDNAs were synthesized using a cDNA synthesis kit (TaKaRa) according to the manufacturer's instructions. RT-PCR was performed using a Real-Time RT-PCR kit (TaKaRa) in combination with the Chromo4 System (BioRad). Time and temperatures for the amplification cycles included: (1) 95°C for 5 min, (2) 30 cycles of 1 min at 95°C, 30 s at 55°C, 30 s at 72°C, and (3) a final extension at 72°C. Oligonucleotide sequences used for the amplification of the galectin-1 gene were: CGAGTGCGAGGCGAGGTG (forward) and CGTTGAAGCGAGGGTTGAAGTG (reverse); and for the b-actin gene: GGAAATCGTGCGTGAC (forward) and ATGCCCAGGAAGGA (reverse). The mRNA expression level of galectin-1 was normalized to b-actin.
DNA Methyltransferases (DNMTs) Activity Assay Total protein from SMMC-7721 cells was extracted in 150 ml lysis buffer (Pierce) at room temperature. Following supersonic shock-wave concussion on ice several times and centrifugation at 12000 rpm for 1 h, supernatants were collected. The Bradford protein assay was used to determine protein concentrations, and the same amount of protein for each sample was subjected to DNMTs activity assay (Epigentek) performed according to the manufacturer's instructions. After incubation, capturing, and developing, enzyme activity for samples and controls was measured on a microplate reader at 450 nm. Normalization of values was achieved using the background absorbance of culture medium alone.
Annexin V Staining and Flow Cytometry Cell apoptosis was measured by annexin V-fluorescein isothiocyanate (FITC) and PI staining using Flow Cytometry assay. Plated SMMC-7721 cells were treated with four protocols as follows: group A, untreated control; group B, DAC alone; group C, CPT alone; and group D, DAC followed by CPT. In group D, cells were treated with 0.1 mM freshly prepared DAC. Treatment was replenished every 24 h and after 72 h, cells were washed with PBS then incubated in drug-free media for 72 h, and finally treated with CPT of 55 mg/ml for 48 h.
Statistical Analyses Each experiment was performed at least in triplicate. Results are expressed as meanϮS.D. Statistical significance was compared between each treated group and control by Dunnett's test in RT-PCR and DNA methyltransferases (DNMTs) activity assay, and by 2-way ANOVA test in MTT assay and flow cytometry assay (SPSS, version 11.0 for Windows; SPSS Inc., Chicago, IL, U.S.A.). Results with pϽ0.05 were considered significantly different from control group.
RESULTS
Isolation and Identification of Galectin-1 Addition of CPT to SMMC-7221 cells resulted in concentration-dependent growth inhibition. An IC 50 value of 55 mg/ml (data not shown) for CPT treatment was used to generate samples for two-dimensional (2D) electrophoresis. The silver-stained gel in Fig. 1 provides a comprehensive view of the major proteins expressed in SMMC-7721. 2D-gels for treated samples and control gels consistently provided good sensitivity and high reproducibility with detection of Ͼ700 silver-stained proteins. High-efficiency matching was achieved in each group. Several differentially expressed proteins in SMMC-7721 cells were observed following treatment with CPT. Among them, 49 protein spots were downregulated and 56 upregulated. Of particular interest was the identification of one protein galectin-1. The inset boxes of Fig. 1 highlight a specific protein that showed decreased expression following treatment with CPT, and was subsequently identified as galectin-1 using MALDI-TOF-MS/MS analysis.
Confirmation of Galectin-1 Identification
To confirm the changes in galectin-1 protein expression observed by 2D-gel electrophoresis, mRNA expression level was evaluated following CPT treatment using RT-PCR analysis. Figure  2 shows the changes in mRNA levels determined for galectin-1 in SMMC-7721 cells. Based on data from RT-PCR analysis, mRNA expression of galectin-1 was downregulated (pϽ0.05) after CPT treatment.
CPT Induces Downregulation of DNMTs The proximal promoter region of the galectin-1 gene is extremely GC- rich and regulation of galectin-1 expression is under the control of the methylation status of its gene promoter. [13] [14] [15] Therefore we hypothesized that DNMTs may be involved in CPT-induced signaling. The time course of DNMT protein levels after CPT treatment is shown in Fig. 3 . The protein levels of DNMTs decreased significantly (pϽ0.05) in a timedependent manner with incubation of SMMC-7721 cells with CPT.
Enhanced Cell Cytotoxicity after DAC and CPT Cotreatment To evaluate whether regulation of DNMTs is associated with CPT-induced cell death, SMMC-7721 cells were pre-treated with the DNMT inhibitor, 5-aza-2Јdeoxycy-tidine (DAC), and cell viability and apoptosis were evaluated after CPT treatment. MTT and flow cytometry assays were used to detect differences in cell proliferation and apoptosis in SMMC-7721 cells, respectively, with and without DAC pre-treatment followed by incubation with CPT for 48 h. DAC treatment alone could not affect cell proliferation and apoptosis in SMMC-7721 compared with blank control group; however inhibition of DNMTs by DAC followed by administration of CPT resulted in significant inhibition of proliferation and induction of apoptosis in SMMC-7721 cells compared with CPT treatment alone (Fig. 4) .
DISCUSSION
In this study, we report the discovery of a novel downstream protein, DNMT, linking topoisomerase I inhibition by CPT leading to growth inhibition and apoptosis in hepatocellular carcinoma SMMC-7721 cells. Moreover, in combination with the DNMT inhibitor DAC, CPT markedly enhanced its antitumor activity. Our results provide new insight into the molecular mechanisms of CPT and the potential to optimize therapies for treatment of hepatocellular carcinomas.
Aberrant DNA methylation and increased expression of DNMTs are features of tumor cells including hepatocellular carcinomas. Three distinct families of DNMT, DNMT1, DNMT2, and DNMT3, have been identified in mammalian cells. Expression of DNMT1 mRNA 16) and protein 17, 18) in hepatocellular carcinomas is significantly higher than in normal or nontumor tissue. DNMT3a and DNMT3b mRNA is also expressed at higher levels in hepatocellular carcinomas than in nonneoplastic liver tissues. 16) These results suggest that overexpression of DNMTs may be due to hepatocarcinogenesis and has made them attractive therapeutic targets. Moreover the DNMTs inhibitor DAC has been reported to prolong disease stabilization of patients with lung cancer and prostate cancer. 19) We demonstrate in this study that CPT inhibites DNMTs protein levels in a time-dependent manner. These hepatocarcinogenesis associated proteins are, to our knowledge, found for the first time as being altered as a consequence of topoisomerase I inhibition by CPT. In addition, we examined the possibility that inhibition of DNMT activity rendered cancer cells more sensitive to cytotoxic agent CPT. As expected, DNMT inhibitor, DAC, was shown to sensitize SMMC-7721 cells to the cytotoxic effect of CPT. Taken together, inhibition of DNMT may represent one of the novel antitumor mechanisms of CPT.
Galectin-1 is a member of the lectin family that has many receptors and is involved in mediating cell adhesion and proliferation as well as tumor metastasis, apoptosis, immune escape, and angiogenesis. Galectin-1 is essential in the development of tumors based on its ability to facilitate interactions between tumor cells and endothelial cells, to support the establishment of metastasis sites, 20) and to induce apoptosis in tumor-infiltrating cytotoxic leukocytes and thereby protect the tumor from detection. 21) Galectin-1 maintains its role in cancer biology by playing a critical role in tumor angiogenesis. 22) In normal liver tissue, galectin-1 expression is barely detectable; however, it is overexpressed in primary hepatocellular carcinoma cells. 14) Moreover, administration of siRNA targeted to galectin-1 increased the sensitivity of siRNA-expressing cells to the cytotoxic effects of SN-38, a CPT derivative, in the glioma cell line, U87 MG. Expression of recombinant galectin-1 partially abrogated the increase in sensitivity observed with siRNA expression. 23) In view of the important role of galectin-1 in tumor biology, we speculate that downregulation of galectin-1 may render cancer cells more susceptible to CPT.
There exist three different families of DNMT genes, DNMT1, DNMT2, and DNMT3. This study has examined only total protein levels of DNMT after CPT treatment. Despite these limitations, this study clearly indicates that DNMT plays an important role in CPT-induced apoptosis and growth inhibition of hepatocellular carcinoma cells. Understanding the molecular mechanisms of CPT may extend the application of CPT to other therapeutic regions for more effective treatment of hepatocellular carcinoma.
Taken together, we provide novel evidence to indicate that CPT can modulate not only galectin-1 gene and protein expression, but also DNMTs protein expression in the human hepatocellular carcinoma cell line, SMMC-7721. Furthermore, sensitization of cancer cells to CPT by pre-treatment with the DNMTs inhibitor, DAC, provides valuable insight into additional options for more effective treatments in hepatomal cancer therapy.
